Investor Spotlight: Taking a Look at Nektar Therapeutics (NASDAQ:NKTR)


For the Current Quarter, the growth estimate for Nektar Therapeutics is -14.3%, while for the Next Quarter the stock growth estimate is 16.7%. Nektar Therapeutics accounts for about 2.0% of Harvey Capital Management Inc.'s holdings, making the stock its 13th largest position. Its position was valued at $28,378,000 an increase of $6,370,000 according to the filing.

Vanguard Gp holds 0.01% in Nektar Therapeutics (NASDAQ:NKTR) or 14.01 million shares. Bank of New York Mellon Corp boosted its stake in Nektar Therapeutics by 0.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 952,443 shares of the biopharmaceutical company's stock valued at $18,620,000 after purchasing an additional 79,510 shares during the last quarter. Finally, American International Group Inc. increased its stake in shares of Nektar Therapeutics by 5.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company's stock valued at $110,000 after acquiring an additional 692 shares during the last quarter. Insiders have sold a total of 1,024,757 shares of company stock valued at $25,974,361 in the last ninety days. The value of the total investment in Nektar Therapeutics increased from $2,187,000 to $2,841,000 a change of 29.9% for the reporting period. The company's revenue for the quarter was up 321.2% on a year-over-year basis. Hedge funds and other institutional investors own 85.85% of the company's stock.

About 9.14 million shares traded or 501.32% up from the average.

In the market the company is trading up from yesterday's close of 32.5. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $33.67. Switching over to some distances from popular moving averages, we see that the stock has been recorded 89.25% away from the 200 day moving average.

Investors are a little more bullish on shares of Nektar Therapeutics lately if you evaluate the fall in short interest.

Health care stocks were slightly lower, with the NYSE Health Care Index falling 0.1% while shares of health care companies in the S&P 500 also were down less than 0.1% as a group. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. While in the same Quarter Previous year, the Actual EPS was $-0.28. Currently Analysts have a mean recommendation of 1.60 on the shares. "Has $6,567,000 Stake in Nektar Therapeutics (NKTR)" was posted by and is owned by of. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of U.S. and global trademark and copyright laws. Vanguard Grp invested 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR).

Interlagos test for McLaren cancelled amid security fears
After the Mercedes incident, Hamilton tweeted that "F1 and the teams need to do more, there's no excuse" as far as safety goes. We are actively involved, but we can not be experts in every city we go to".

Several analysts recently commented on the company. On November 8 Jefferies Group LLC kept the company rating at "Buy" with a current price target of $35.00.

Rothschild Asset Management Inc says it bought 56,672 shares in the previous quarter increasing its exposure to Nektar Therapeutics by 5.0%. Aegis Capital maintained the stock with "Buy" rating in Thursday, May 11 report.

COPYRIGHT VIOLATION WARNING: "Nektar Therapeutics (NKTR) Coverage Initiated by Analysts at Canaccord Genuity" was posted by BBNS and is owned by of BBNS. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the company's stock.

Lannett has an analyst consensus of Moderate Buy, with a price target consensus of $24.75.

In other news, SVP Stephen K. Doberstein sold 1,701 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, August 16th. Also published the news titled: "Biotech Stocks on Investors' Radar - Nektar Therapeutics, Ophthotech, PTC ..." on October 16, 2017. Following the completion of the sale, the senior vice president now directly owns 31,102 shares in the company, valued at approximately $600,890.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The total dollar value of all 155.35 million outstanding shares is 5.05 billion. Following the acquisition, the director now directly owns 121,333 shares of the company's stock, valued at $1,637,995.50. The disclosure for this sale can be found here.